论文部分内容阅读
本文报知了１０名慢性阻塞性肺疾病（ＣＯＰＤ）患者服用硝苯啶前后稳态时氨茶碱药物动力学和药效学的变化．整个实验分二个期，Ⅰ期为单服氨茶碱３天至稳态；Ⅱ期为二药合并用药５天。各期测得的氨茶碱药物动力学参数，ＣｓｓＴＰＫ分别为１２．９１，１１．３μｇ／ｍＬ；ＣＬｓｓ分别为０．０４５，０．０５２Ｌ／ｈ／Ｋｇ；分别为１０．０９，９．３４ｈ；Ｖｓｓｄ分别为０．６２８，０．６４５Ｌ／Ｋｇ。药效学参数呼吸道最大通气量（ＰＥＦＲ）分别为２８３．３０，２９２．２６１Ｌ／ｍｉｍ。结果经统计学处理，与Ⅰ期比较Ⅱ期的药物动力学参数（ｔ１／２，ＣＬｓｓ，ＣｓｓＴＰＫ，Ｖｓｓｄ和药效学参数（ＰＥＦＲ）差异均无显著意义（Ｐ＞０．０５），表明硝苯啶与氨茶碱联合用药时稳态时茶碱药物动力学参数和药效学参数（ＰＥＦＲ）差异均无显著意意义（Ｐ＞０．０５），表明硝苯啶与氨茶碱联合用药时稳态时茶碱药物动力学参数和药效学参数无显著影响。
This article reports the pharmacokinetics and pharmacodynamics of aminophylline in 10 patients with chronic obstructive pulmonary disease (COPD) before and after taking nifedipine. The whole experiment was divided into two phases, stage I was single-dose aminophylline for three days to steady-state; phase II was combined with two drugs for five days. The pharmacokinetic parameters of aminophylline in each phase were 12.91 and 11.3 μg / mL, respectively; CLss were 0.045 and 0.052 L / h / Kg, respectively, which were 10.09 and 9.34 h ; Vssd respectively 0.628,0.645L / Kg. Pharmacodynamic parameters of respiratory tract maximum ventilation (PEFR) were 283.30,292.261L / mim. Results There was no significant difference in the pharmacokinetic parameters (t1 / 2, CLss, CssTPK, Vssd and pharmacodynamics parameter (PEFR)) between the two groups in the first phase (P> 0.05) There were no significant differences in the pharmacokinetic parameters and pharmacodynamic parameters (PEFR) between the phenyridine and the aminophylline in the steady state (P> 0.05), indicating that combination of nifedipine and aminophylline There was no significant effect of theophylline pharmacokinetic parameters and pharmacodynamic parameters at steady state.